PRZ-ROSUVASTATIN TABLET
国家: 加拿大
语言: 英文
来源: Health Canada
产品特点
(SPC)
23-09-2020
该产品的某些文档当前不可用，您可以向我们的客户服务发送请求，我们将在获得它们后尽快通知您。
发送请求。
发送请求。
有效成分:
ROSUVASTATIN (ROSUVASTATIN CALCIUM)
可用日期:
PHARMARIS CANADA INC
ATC代码:
C10AA07
INN（国际名称）:
ROSUVASTATIN
剂量:
40MG
药物剂型:
TABLET
组成:
ROSUVASTATIN (ROSUVASTATIN CALCIUM) 40MG
给药途径:
ORAL
每包单位数:
15G/50G
处方类型:
Prescription
治疗领域:
HMG-COA REDUCTASE INHIBITORS
產品總結:
Active ingredient group (AIG) number: 0148963003; AHFS:
授权状态:
APPROVED
授权日期:
2020-09-25
产品特点
Page 1 of 43
PRODUCT MONOGRAPH
PR
PRZ-ROSUVASTATIN
Rosuvastatin Calcium Tablets, USP
Tablets: 5 mg, 10 mg, 20 mg and 40 mg of rosuvastatin (as rosuvastatin
calcium)
Lipid Metabolism Regulator
Pharmaris Canada Inc.
8310-130 Street, Suite 102,
Surrey, British Columbia
Canada V3W 8J9
DATE OF PREPARATION: September 23,
2020
CONTROL NO: 234091
Page 2 of 43
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
................................................................. 3
INDICATIONS AND CLINICAL
USE.......................................................................
3
CONTRAINDICATIONS
............................................................................................
4
WARNINGS AND PRECAUTIONS
..........................................................................
5
ADVERSE REACTIONS
..........................................................................................
10
DRUG INTERACTIONS
...........................................................................................
14
DOSAGE AND ADMINISTRATION
.......................................................................
21
OVERDOSAGE
.........................................................................................................
23
ACTION AND CLINICAL PHARMACOLOGY
..................................................... 23
STORAGE AND STABILITY
..................................................................................
25
DOSAGE FORMS, COMPOSITION AND PACKAGING
...................................... 26
PART II: SCIENTIFIC INFORMATION
.............................................................................
27
PHARMACEUTICAL INFORMATION
.................................................................. 27
CLINICAL
TRIALS...................................................................................................
28
DETAILED PHARMACOLOGY
..............................................................................
31
TOXICO
阅读完整的文件
